Brands
Johnson & Johnson splits into two as big pharma downsizes
Oral Covid-19 drugs: Merck’s molnupiravir and its closest rivals
Oral JAK inhibitors unlikely to be totally shut out in eczema by black box warning
Why has the WHO asked governments to delay Covid-19 booster jabs?
Insurers to squeeze JAK inhibitor access in chronic conditions after FDA safety warning
EU approval of Novartis’ Kesimpta offers treatment that can be self-administered, but Roche’s Ocrevus will retain MS market position
Boehringer Ingelheim reports positive business growth in 2020
